163 related articles for article (PubMed ID: 32959232)
1. Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer.
Zhang Y; Xu Y; Wang D; Kuang T; Wu W; Xu X; Jin D; Lou W
Int J Clin Oncol; 2021 Jan; 26(1):135-144. PubMed ID: 32959232
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
3. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
4. Preoperative C-reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma.
Ikuta S; Aihara T; Yamanaka N
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e109-e114. PubMed ID: 30632282
[TBL] [Abstract][Full Text] [Related]
5. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio.
Bhatti I; Peacock O; Lloyd G; Larvin M; Hall RI
Am J Surg; 2010 Aug; 200(2):197-203. PubMed ID: 20122680
[TBL] [Abstract][Full Text] [Related]
6. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma.
Smith RA; Bosonnet L; Raraty M; Sutton R; Neoptolemos JP; Campbell F; Ghaneh P
Am J Surg; 2009 Apr; 197(4):466-72. PubMed ID: 18639229
[TBL] [Abstract][Full Text] [Related]
7. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection.
Shirai Y; Shiba H; Sakamoto T; Horiuchi T; Haruki K; Fujiwara Y; Futagawa Y; Ohashi T; Yanaga K
Surgery; 2015 Aug; 158(2):360-5. PubMed ID: 26032829
[TBL] [Abstract][Full Text] [Related]
8. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
[TBL] [Abstract][Full Text] [Related]
9. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer.
Sakamoto T; Saito H; Amisaki M; Tokuyasu N; Honjo S; Fujiwara Y
Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):278-284. PubMed ID: 30987900
[TBL] [Abstract][Full Text] [Related]
10. Association of preoperative total lymphocyte count with prognosis in resected left-sided pancreatic cancer.
Rho SY; Hwang HK; Chong JU; Yoon DS; Lee WJ; Kang CM
ANZ J Surg; 2019 May; 89(5):503-508. PubMed ID: 30836428
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
[TBL] [Abstract][Full Text] [Related]
12. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
13. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
14. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
15. Prognostic stratification in patients with pancreatic ductal adenocarcinoma after curative resection based on preoperative pancreatic contrast-enhanced CT findings.
Li D; Wang L; Cai W; Liang M; Ma X; Zhao X
Eur J Radiol; 2022 Jun; 151():110313. PubMed ID: 35447500
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy.
Qiao G; Ilagan CH; Fernandez-Del Castillo C; Ferrone CR; Janseen QP; Balachandran VP; Sell NM; Drebin JA; Hank T; Kingham TP; D'Angelica MI; Jarnagin WR; Lillemoe KD; Wei AC; Qadan M
Surgery; 2022 Oct; 172(4):1228-1235. PubMed ID: 35931556
[TBL] [Abstract][Full Text] [Related]
17. Serum aspartate aminotransferase is an adverse prognostic indicator for patients with resectable pancreatic ductal adenocarcinoma.
He M; Liu Y; Huang H; Wu J; Wu J; Wang R; Wang D
Lab Med; 2023 Nov; 54(6):608-612. PubMed ID: 37027310
[TBL] [Abstract][Full Text] [Related]
18. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.
van Roessel S; Kasumova GG; Verheij J; Najarian RM; Maggino L; de Pastena M; Malleo G; Marchegiani G; Salvia R; Ng SC; de Geus SW; Lof S; Giovinazzo F; van Dam JL; Kent TS; Busch OR; van Eijck CH; Koerkamp BG; Abu Hilal M; Bassi C; Tseng JF; Besselink MG
JAMA Surg; 2018 Dec; 153(12):e183617. PubMed ID: 30285076
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.
Maire F; Hammel P; Terris B; Paye F; Scoazec JY; Cellier C; Barthet M; O'Toole D; Rufat P; Partensky C; Cuillerier E; Lévy P; Belghiti J; Ruszniewski P
Gut; 2002 Nov; 51(5):717-22. PubMed ID: 12377813
[TBL] [Abstract][Full Text] [Related]
20. Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection.
Jomrich G; Gruber ES; Winkler D; Hollenstein M; Gnant M; Sahora K; Schindl M
J Gastrointest Surg; 2020 Mar; 24(3):610-618. PubMed ID: 30923999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
